ArticleEuropean journal of nuclear medicine and molecular imaging2014
Thyroid nodules with indeterminate cytology: molecular imaging with ⁹⁹mTc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma gene expression classifier.
Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Pooled it
- Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2017Pooled it
- Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology.Oncotarget · 2017Pooled it
- Molecular imaging with (99m)Tc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison.European journal of nuclear medicine and molecular imaging · 2016Trial
- The MIBI is dead, long live the MIBI: revisiting [99mTc]Tc-Sestamibi thyroid scintigraphy in the era of ultrasound, cytology, molecular diagnostic, and 18 F-FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- The management of cytologically indeterminate thyroid nodules in clinical practice: A contemporary perspective with focus on molecular imaging.Endocrine · 2025Review
- Integrated Diagnostics of Thyroid Nodules.Cancers · 2024Review
- Diagnostic Performance ofDiagnostics (Basel, Switzerland) · 2022Article
- Radioisotope imaging for discriminating benign from malignant cytologically indeterminate thyroid nodules.Gland surgery · 2019Review
- Cancer Rate of the Indeterminate Lesions at Low or High Risk According to Italian System for Reporting of Thyroid FNA.Frontiers in endocrinology · 2018Article
- Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2016Article
- Article
- Thyroid core needle biopsy: taking stock of the situation.Endocrine · 2015Article
- Management of thyroid nodules incidentally discovered on MIBI scanning for primary hyperparathyroidism.Langenbeck's archives of surgery · 2015Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the cost-effectiveness of (99m)Tc-methoxyisobutylisonitrile (MIBI) thyroid scintigraphy and the Afirma gene expression classifier for the assessment of cytologically indeterminate thyroid nodules.
methodsA decision tree model was used. Costs were calculated from the perspective of the German health insurance system. The robustness of the results was assessed with probabilistic sensitivity analyses using a Monte Carlo simulation.
resultsLife expectancy was 34.3 years (estimated costs per patient €1,459 - €2,224) for the MIBI scan and 34.1 years (estimated costs €3,560 - €4,071) for the molecular test. These results were confirmed by the Monte Carlo simulation.
conclusionMIBI thyroid scintigraphy is more cost-effective than the gene expression classifier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.